In order to be optimally equipped for the future, MLL Münchner Leukämielabor founded the affiliate company MLLi ("i" here stands for "innovation") to focus on technological specialization. Because innovation is increasingly focusing on software, the newly established company will be dedicated to the digital processing of data from leukemia diagnostics. Among other things, MLLi will provide scientists, researchers, doctors, and biologists with browser-based tools for the interpretation of molecular, cytogenetic and immunophenotype data for hematological diagnoses.
This is where the new MLLi comes in: With the project MLLi:db ("db" for "database"), we will anonymously publish manually curated data collected over the past 12 years from the sequencing of diagnostic samples in an ISO 15189 accredited environment at the MLL. Each variant in MLLi:db is classified in a 3-level system. ("pathogenic", "benign" or "variant with unknown significance (VUS)"), where the variant was seen in at least five different patients and unambiguously classified by an expert at MLL considering other diagnostic procedures and the diagnosis of the patient.
Over time, as databases and various procedures have grown and developed, access to these resources has transformed from being a blessing into a curse. Apart from frequency data from the laboratory's own database, it will also enable convenient access to the following sources: COSMIC, dbSNP, gnomAD, ClinVar and dbNSFP. The database will be published quarterly with new and updated information. The second version consist of 1,752 variants in 104 genes which were collected using data from 232,539 samples. Access to the data is provided via web application.